TITE‐gBOIN: Time‐to‐event Bayesian optimal interval design to accelerate dose‐finding accounting for toxicity grades von Takeda, Kentaro, Xia, Qing, Liu, Shufang, Rong, Alan

Volltext

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic C... von PEETERS, Marc, JAY PRICE, Timothy, STRICKLAND, Andrew H, WILSON, Gregory, CIULEANU, Tudor-Eliade, ROMAN, Laslo, VAN CUTSEM, Eric, TZEKOVA, Valentina, COLLINS, Simon, OLINER, Kelly S, RONG, Alan, GANSERT, Jennifer, CERVANTES, Andrés, SOBRERO, Alberto F, DUCREUX, Michel, HOTKO, Yevhen, ANDRE, Thierry, CHAN, Emily, LORDICK, Florian, PUNT, Cornelis J. A

Volltext

Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials von SIDHU, Roger, RONG, Alan, DAHLBERG, Steve

Volltext

Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers von Takeda, Kentaro, Liu, Shufang, Rong, Alan

Volltext

Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects von Diao, Guoqing, Zeng, Donglin, Ibrahim, Joseph G., Rong, Alan, Lee, Oliver, Zhang, Kathy, Chen, Qingxia

Volltext

An adaptive biomarker basket design in phase II oncology trials von Liu, Shufang, Takeda, Kentaro, Rong, Alan

Volltext

Weighted log‐rank test for time‐to‐event data in immunotherapy trials with random delayed treatment effect and cure rate von Liu, Shufang, Chu, Chenghao, Rong, Alan

Volltext

Study design of single‐arm phase II immunotherapy trials with long‐term survivors and random delayed treatment effect von Chu, Chenghao, Liu, Shufang, Rong, Alan

Volltext

Flexible combination of multiple diagnostic biomarkers to improve diagnostic accuracy von Xu, Tu, Fang, Yixin, Rong, Alan, Wang, Junhui

Volltext

Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted Designs von Li, Ran, Takeda, Kentaro, Rong, Alan

Volltext

Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer von Hecht, J. Randolph, Douillard, Jean-Yves, Schwartzberg, Lee, Grothey, Axel, Kopetz, Scott, Rong, Alan, Oliner, Kelly S, Sidhu, Roger

Volltext

Pattern mixture models for clinical validation of biomarkers in the presence of missing data von Gao, Fei, Dong, Jun, Zeng, Donglin, Rong, Alan, Ibrahim, Joseph G.

Volltext

Estimation of delay time in survival data with delayed treatment effect von Li, Wei, Chen, Sophie Yu-Pu, Rong, Alan

Volltext

Biomarker threshold adaptive designs for survival endpoints von Diao, Guoqing, Dong, Jun, Zeng, Donglin, Ke, Chunlei, Rong, Alan, Ibrahim, Joseph G

Volltext

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer von Douillard, Jean-Yves, Oliner, Kelly S, Siena, Salvatore, Tabernero, Josep, Burkes, Ronald, Barugel, Mario, Humblet, Yves, Bodoky, Gyorgy, Cunningham, David, Jassem, Jacek, Rivera, Fernando, Kocákova, Ilona, Ruff, Paul, Błasińska-Morawiec, Maria, Šmakal, Martin, Canon, Jean Luc, Rother, Mark, Williams, Richard, Rong, Alan, Wiezorek, Jeffrey, Sidhu, Roger, Patterson, Scott D

Volltext

RAS Mutations in Colorectal Cancer von Sunakawa, Yu, Lenz, Heinz-Josef, Ichikawa, Wataru, Douillard, Jean-Yves, Rong, Alan, Sidhu, Roger

Volltext

The PRIME trial: Quality-adjusted survival in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with panitumumab plus FOLFOX versus... von Wang, Jianmin, Dong, Jun, Hechmati, Guy, Rong, Alan, Maglinte, Gregory, Barber, Beth L., Douillard, Jean-Yves

Volltext

Quality-adjusted survival in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with panitumumab plus FOLFOX versus FOLFOX alone in t... von Wang, Jianmin, Dong, Jun, Johnson, Patrick, Maglinte, Gregory A., Rong, Alan, Barber, Beth L., Douillard, Jean-Yves

Volltext

PD-0019 Benefit of Panitumumab (pmab) as Monotherapy in Patients with WT KRAS mCRC: A Number-Needed-To-Treat (NNT) Analysis von Van Cutsem, Eric, Rong, Alan, Humblet, Yves, Siena, Salvatore, Braun, Stephan, Sidhu, Roger, Peeters, Marc

Volltext

O-0014 Effect of Post-Protocol anti-EGFR mAb Therapy on Survival Outcomes in Patients with Wild-Type Kras MCRC Treated with Panitumumab Plus Chemotherapy von Douillard, Jean-Yves, Peeters, Marc, Rong, Alan, Siena, Salvatore, Braun, Stephan, Sidhu, Roger, Price, Timothy

Volltext